These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 9784993)
1. Endometrial intraepithelial carcinoma diagnosed by brush cytology and p53 immunostaining, and confirmed by hysterectomy. Maksem JA; Lee SS Diagn Cytopathol; 1998 Oct; 19(4):284-7. PubMed ID: 9784993 [TBL] [Abstract][Full Text] [Related]
2. Endometrial intraepithelial carcinoma: a case report and brief review. Ram M; Bharadwaj M; Yadav R Indian J Pathol Microbiol; 2008; 51(4):512-4. PubMed ID: 19008579 [TBL] [Abstract][Full Text] [Related]
3. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Sherman ME; Bur ME; Kurman RJ Hum Pathol; 1995 Nov; 26(11):1268-74. PubMed ID: 7590703 [TBL] [Abstract][Full Text] [Related]
4. Endometrial collection and interpretation using the Tao brush and the CytoRich fixative system: a feasibility study. Maksem J; Sager F; Bender R Diagn Cytopathol; 1997 Nov; 17(5):339-46. PubMed ID: 9360046 [TBL] [Abstract][Full Text] [Related]
5. Direct uterine sampling with the Tao brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia: a feasibility study. Kipp BR; Medeiros F; Campion MB; Distad TJ; Peterson LM; Keeney GL; Halling KC; Clayton AC Cancer; 2008 Aug; 114(4):228-35. PubMed ID: 18548528 [TBL] [Abstract][Full Text] [Related]
6. Endometrial brush cytology of advanced postmenopausal endometrium: does endometrial intraepithelial neoplasia exist in the absence of hyperplasia? Maksem JA Diagn Cytopathol; 1998 Nov; 19(5):338-43. PubMed ID: 9812226 [TBL] [Abstract][Full Text] [Related]
7. Management of endometrial precancers. Trimble CL; Method M; Leitao M; Lu K; Ioffe O; Hampton M; Higgins R; Zaino R; Mutter GL; Obstet Gynecol; 2012 Nov; 120(5):1160-75. PubMed ID: 23090535 [TBL] [Abstract][Full Text] [Related]
8. Expression of p53 in imprint smears of endometrial carcinoma. Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025 [TBL] [Abstract][Full Text] [Related]
9. Nuclear Beta-Catenin Expression in Endometrioid Intraepithelial Neoplasia (Atypical Hyperplasia) Does Not Predict Carcinoma on Subsequent Hysterectomy. Wright MF; Fitzlaff S; Wyeth A; Zaragoza-Watkins M; Podoll MB; Quick CM; Watkins JC Int J Gynecol Pathol; 2021 May; 40(3):240-247. PubMed ID: 32897964 [TBL] [Abstract][Full Text] [Related]
11. Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion? Roelofsen T; van Kempen LC; van der Laak JA; van Ham MA; Bulten J; Massuger LF Int J Gynecol Cancer; 2012 Mar; 22(3):457-64. PubMed ID: 22249577 [TBL] [Abstract][Full Text] [Related]
12. Prediction of coexistent carcinomas risks by subjective EIN diagnosis and comparison with WHO classification in endometrial hyperplasias. Yang YF; Liao YY; Peng NF; Li LQ; Xie SR; Wang RB Pathol Res Pract; 2012 Dec; 208(12):708-12. PubMed ID: 23044462 [TBL] [Abstract][Full Text] [Related]
13. Endometrial adenocarcinoma in situ in complex atypical hyperplasia: correlation with findings in subsequent hysterectomy specimen. Ventura KC; Popiolek D; Mittal K Int J Surg Pathol; 2004 Jul; 12(3):225-30. PubMed ID: 15306934 [TBL] [Abstract][Full Text] [Related]
14. A case of serous endometrial intraepithelial carcinoma with p53 positivity for six years. Kaku S; Moriya T; Ushioda N; Nakai Y; Shimoya K; Nakamura T J Obstet Gynaecol Res; 2012 Feb; 38(2):455-60. PubMed ID: 22176439 [TBL] [Abstract][Full Text] [Related]
15. Clonal evolution in paired endometrial intraepithelial neoplasia/atypical hyperplasia and endometrioid adenocarcinoma. Russo M; Broach J; Sheldon K; Houser KR; Liu DJ; Kesterson J; Phaeton R; Hossler C; Hempel N; Baker M; Newell JM; Zaino R; Warrick JI Hum Pathol; 2017 Sep; 67():69-77. PubMed ID: 28712776 [TBL] [Abstract][Full Text] [Related]
16. [Endometrial carcinoma in situ. Morphological and immunohistochemical aspects]. Plămădeală P; Teleman S; Mihailovici MS Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):654-6. PubMed ID: 14756081 [TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade. Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic p53 immunostaining of endobiliary brush cytology: preoperative cytology compared with the surgical specimen. Tascilar M; Sturm PD; Caspers E; Smit M; Polak MM; Huibregtse K; Noorduyn LA; Offerhaus GJ Cancer; 1999 Oct; 87(5):306-11. PubMed ID: 10536357 [TBL] [Abstract][Full Text] [Related]
19. Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma. Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P Diagn Cytopathol; 2013 Mar; 41(3):212-7. PubMed ID: 21965052 [TBL] [Abstract][Full Text] [Related]
20. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]